Incidence of Dysphagia and Comorbidities in Patients with Cervical Dystonia, Analyzed by Botulinum Neurotoxin Treatment Exposure
Dysphagia is prevalent in patients with cervical dystonia (CD) and is a potential adverse event in patients treated with botulinum neurotoxin (BoNT) for CD. Real-world studies may provide a better understanding of the incidence and potential risk factors of dysphagia after BoNT administration. This...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-03-01
|
| Series: | Toxins |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6651/17/3/148 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850088161725644800 |
|---|---|
| author | Richard L. Barbano Bahman Jabbari Marjan Sadeghi Ahunna Ukah Emma Yue Kimberly Becker Ifantides Nuo-Yu Huang David Swope |
| author_facet | Richard L. Barbano Bahman Jabbari Marjan Sadeghi Ahunna Ukah Emma Yue Kimberly Becker Ifantides Nuo-Yu Huang David Swope |
| author_sort | Richard L. Barbano |
| collection | DOAJ |
| description | Dysphagia is prevalent in patients with cervical dystonia (CD) and is a potential adverse event in patients treated with botulinum neurotoxin (BoNT) for CD. Real-world studies may provide a better understanding of the incidence and potential risk factors of dysphagia after BoNT administration. This retrospective cohort study used longitudinal patient-level data from Optum’s de-identified Market Clarity Data to evaluate rates of dysphagia in patients with CD exposed and unexposed to BoNT. Patients ≥18 years of age with ≥2 CD diagnoses ≥30 days apart during the study period (1 January 2017–30 September 2021) who had ≥180 days of continuous health plan enrollment prior to the cohort entry date (first CD diagnosis) were included. Overall, the mean (SD) age of all CD patients (Cohort 1; N = 81,884) was 54.00 (16.21) years, and they were mostly female (67.9%) and white (76.96%). BoNT-Exposed patients (Cohort 2; N = 19,244) had a higher incidence of dysphagia (16.3%) and comorbid conditions when compared with BoNT-Unexposed patients (Cohort 3; N = 61,154 [12.1%]). Overall, patients with pre-existing dysphagia, other dystonias, and comorbid neurologic conditions at baseline also had higher proportions of dysphagia. This real-world analysis indicates that comorbid conditions predispose patients with CD to a greater dysphagia risk during treatment. |
| format | Article |
| id | doaj-art-4865fee8b8af42ee8d12a4ebe6c32213 |
| institution | DOAJ |
| issn | 2072-6651 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Toxins |
| spelling | doaj-art-4865fee8b8af42ee8d12a4ebe6c322132025-08-20T02:43:04ZengMDPI AGToxins2072-66512025-03-0117314810.3390/toxins17030148Incidence of Dysphagia and Comorbidities in Patients with Cervical Dystonia, Analyzed by Botulinum Neurotoxin Treatment ExposureRichard L. Barbano0Bahman Jabbari1Marjan Sadeghi2Ahunna Ukah3Emma Yue4Kimberly Becker Ifantides5Nuo-Yu Huang6David Swope7Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642, USADepartment of Neurology, Yale School of Medicine, New Haven, CT 06510, USAAbbVie, Irvine, CA 92612, USAAbbVie, Irvine, CA 92612, USAAbbVie, Irvine, CA 92612, USAAbbVie, Irvine, CA 92612, USAAbbVie, Irvine, CA 92612, USADepartment of Neurology, University of California, Irvine, CA 92697, USADysphagia is prevalent in patients with cervical dystonia (CD) and is a potential adverse event in patients treated with botulinum neurotoxin (BoNT) for CD. Real-world studies may provide a better understanding of the incidence and potential risk factors of dysphagia after BoNT administration. This retrospective cohort study used longitudinal patient-level data from Optum’s de-identified Market Clarity Data to evaluate rates of dysphagia in patients with CD exposed and unexposed to BoNT. Patients ≥18 years of age with ≥2 CD diagnoses ≥30 days apart during the study period (1 January 2017–30 September 2021) who had ≥180 days of continuous health plan enrollment prior to the cohort entry date (first CD diagnosis) were included. Overall, the mean (SD) age of all CD patients (Cohort 1; N = 81,884) was 54.00 (16.21) years, and they were mostly female (67.9%) and white (76.96%). BoNT-Exposed patients (Cohort 2; N = 19,244) had a higher incidence of dysphagia (16.3%) and comorbid conditions when compared with BoNT-Unexposed patients (Cohort 3; N = 61,154 [12.1%]). Overall, patients with pre-existing dysphagia, other dystonias, and comorbid neurologic conditions at baseline also had higher proportions of dysphagia. This real-world analysis indicates that comorbid conditions predispose patients with CD to a greater dysphagia risk during treatment.https://www.mdpi.com/2072-6651/17/3/148cervical dystoniabotulinum neurotoxindysphagiaincidencecomorbidityreal-world evidence |
| spellingShingle | Richard L. Barbano Bahman Jabbari Marjan Sadeghi Ahunna Ukah Emma Yue Kimberly Becker Ifantides Nuo-Yu Huang David Swope Incidence of Dysphagia and Comorbidities in Patients with Cervical Dystonia, Analyzed by Botulinum Neurotoxin Treatment Exposure Toxins cervical dystonia botulinum neurotoxin dysphagia incidence comorbidity real-world evidence |
| title | Incidence of Dysphagia and Comorbidities in Patients with Cervical Dystonia, Analyzed by Botulinum Neurotoxin Treatment Exposure |
| title_full | Incidence of Dysphagia and Comorbidities in Patients with Cervical Dystonia, Analyzed by Botulinum Neurotoxin Treatment Exposure |
| title_fullStr | Incidence of Dysphagia and Comorbidities in Patients with Cervical Dystonia, Analyzed by Botulinum Neurotoxin Treatment Exposure |
| title_full_unstemmed | Incidence of Dysphagia and Comorbidities in Patients with Cervical Dystonia, Analyzed by Botulinum Neurotoxin Treatment Exposure |
| title_short | Incidence of Dysphagia and Comorbidities in Patients with Cervical Dystonia, Analyzed by Botulinum Neurotoxin Treatment Exposure |
| title_sort | incidence of dysphagia and comorbidities in patients with cervical dystonia analyzed by botulinum neurotoxin treatment exposure |
| topic | cervical dystonia botulinum neurotoxin dysphagia incidence comorbidity real-world evidence |
| url | https://www.mdpi.com/2072-6651/17/3/148 |
| work_keys_str_mv | AT richardlbarbano incidenceofdysphagiaandcomorbiditiesinpatientswithcervicaldystoniaanalyzedbybotulinumneurotoxintreatmentexposure AT bahmanjabbari incidenceofdysphagiaandcomorbiditiesinpatientswithcervicaldystoniaanalyzedbybotulinumneurotoxintreatmentexposure AT marjansadeghi incidenceofdysphagiaandcomorbiditiesinpatientswithcervicaldystoniaanalyzedbybotulinumneurotoxintreatmentexposure AT ahunnaukah incidenceofdysphagiaandcomorbiditiesinpatientswithcervicaldystoniaanalyzedbybotulinumneurotoxintreatmentexposure AT emmayue incidenceofdysphagiaandcomorbiditiesinpatientswithcervicaldystoniaanalyzedbybotulinumneurotoxintreatmentexposure AT kimberlybeckerifantides incidenceofdysphagiaandcomorbiditiesinpatientswithcervicaldystoniaanalyzedbybotulinumneurotoxintreatmentexposure AT nuoyuhuang incidenceofdysphagiaandcomorbiditiesinpatientswithcervicaldystoniaanalyzedbybotulinumneurotoxintreatmentexposure AT davidswope incidenceofdysphagiaandcomorbiditiesinpatientswithcervicaldystoniaanalyzedbybotulinumneurotoxintreatmentexposure |